The 2023 TB HLM Affected Communities and Civil Society Coordination Hub has been constituted to support and provide a platform for the affected communities and the civil society to engage with all processes of the upcoming 2023 UN High-Level Meeting on TB (TB HLM) scheduled for September this year in New York, USA. The Hub is hosted by the Global Fund Advocates Network (GFAN) and supported by the Stop TB Partnership.

A new state-of-the-art method that measures the amounts of drugs and lipids (fats) in individual cells could help health professionals target more effective treatments for diseases such as TB.

In 1921, the first effective tuberculosis (TB) vaccine was used on human subjects to help protect against this lethal disease. Yet, 100 years later in 2021, more than 1.6 million people died from TB across the world, according to the World Health Organization (WHO), making it the top killer infection once again. There is now an urgent need for new vaccine options to help stop this historical killer.

Over two-thirds of people with symptoms of tuberculosis initially seek care in the private sector. TB is a disease that thrives in areas with poor living conditions such as overcrowded spaces and poorly ventilated housing, and among those with weakened immune systems due to living with HIV, diabetes, or undernutrition.

LA JOLLA, Calif. and CAMBRIDGE, Mass., Feb. 15, 2023 /PRNewswire/ -- Calibr, a division of Scripps Research dedicated to the "bench to bedside" development of transformative medicines, and the Bill & Melinda Gates Medical Research Institute (Gates MRI), today announced a strategic licensing agreement to advance development of a novel investigational compound for tuberculosis treatment. Under the agreement, Calibr is granting Gates MRI an exclusive license to continue the development of the investigational compound CLB073 for tuberculosis treatment. Calibr will transition CLB073 to Gates MRI for further development.

RESIST-TB released its February 2023 newsletter with the latest research publications on drug-resistant TB.

Dose escalation, guided by therapeutic drug monitoring, is an effective method to achieve target levels of rifampicin in those critically ill with TB.

The World Health Organization (WHO) released a compilation of best practices that includes case studies on adaptation and implementation of WHO’s Multisectoral Accountability Framework to end TB (MAF-TB) to support effective collaboration and accountability of governments and stakeholders at the global, regional and country levels to propel progress towards ending the TB epidemic.  

National Tuberculosis and Leprosy Elimination Program (NTLEP) Manager, James Mpunga, has disclosed that Malawi is on the right course towards achieving the reduction of the incidences of tuberculosis by over 90 percent by 2030.

The EU Health Policy Platform Thematic Network on HIV, TB and viral hepatitis will host a webinar on 16 February 2023 providing an overview of key standards of care for people living with or most affected by HIV/AIDS, viral hepatitis (VH), TB (especially drug-resistant) and gaps. It will also look at ways to ensure continued prevention and care for displaced and mobile people and other migrant populations.